All of those assets require money to move forward. Provista Labs was supposed to provide the cash flow to make that happen. But political forces ended the Covid pandemic and stopped testing and tracking numbers of infected, so Provista revenue for Covid testing dried up. Anyone with half a brain realizes that Covid is far from over. Just look at wastewater testing results that GC frequently links to on Twitter. Wastewater is loaded with Covid virus and the trend is going higher. That means lots of folks still have active virus. Hardly anyone is getting boosters, nor wearing masks, nor social distancing, nor getting tested when they come down with fever, sore throats, coughing, etc. They are being told it's summer flu because no one bothers to test for Covid. "It can't be Covid" they are told by doctors.
So it's clear to me Provista won't be supplying the cash needed to move other assets forward, at least not from Covid testing. The sepsis testing seems like a good move, but we haven't seen any revenue figures for that testing yet. But Long Covid is growing by leaps and bounds due to misinformation and lack of knowledge. Tollovid is going to shine in Long Covid treatment, IMO. I believe we will get funding through a partner for Tollovid and Tollovir testing and when those results are in, Todos will have plenty of cash to continue moving Videssa and Lympro to commercialization. Todos Botanicals should help generate income as well. But everything has been delayed because of the Provista Labs downturn in Covid testing, which was the primary source of funds during the pandemic. I'm holding my position and still adding shares. I trust my instincts and DD on this, but if I'm wrong it's my money to lose, and I will own the loss, and I won't be blaming the CEO or anyone else. And I certainly won't be posting here crying about it. Too many other great investments to focus on. Todos is my only penny stock.
Knowing what I know, I continue taking Tollovid daily and keep several bottles in reserve. Covid and Long Covid not happening here.
